A review of bispecific antibodies and antibody constructs in oncology and clinical challenges
Frans V. SuursDepartment of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, the NetherlandsMarjolijn N. Lub–de HoogeDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, the NetherlandsElisabeth G.E. de VriesDepartment of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, the NetherlandsDerk Jan A. de GrootDepartment of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. Electronic address: [email protected]
2019en
ABI
Аннотация
Bispecific antibodies (bsAbs) are antibodies that bind two distinct epitopes to cancer.. For use in oncology, one bsAb has been approved and 57 bsAbs are in clinical trials, none of which has reached phase 3. These bsAbs show great variability in design and mechanism of action. The various designs are often linked to the mechanisms of actions. The majority of bsAbs engage immune cells to destroy tumor cells. However, some bsAbs are also used to deliver payloads to tumors or to block tumor signaling pathways. This review provides insight into the choice of construct for bsAbs, summarizes the clinical development of bsAbs in oncology and identifies subsequent challenges.
Перевод пока недоступен
Идентификаторы
Цитирования и источники
Цитирований: 2Использованных источников: 0